- Home
- INSW vs CNTA Comparison
INSW vs CNTA Comparison
Compare INSW & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- CNTA
- Stock Information
- Founded
- INSW 1999
- CNTA 2020
- Country
- INSW United States
- CNTA United Kingdom
- Employees
- INSW N/A
- CNTA N/A
- Industry
- INSW Semiconductors
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- CNTA Health Care
- Exchange
- INSW Nasdaq
- CNTA Nasdaq
- Market Cap
- INSW 1.8B
- CNTA 1.9B
- IPO Year
- INSW N/A
- CNTA 2021
- Fundamental
- Price
- INSW $41.01
- CNTA $16.56
- Analyst Decision
- INSW Buy
- CNTA Strong Buy
- Analyst Count
- INSW 2
- CNTA 11
- Target Price
- INSW $52.00
- CNTA $28.90
- AVG Volume (30 Days)
- INSW 517.1K
- CNTA 853.6K
- Earning Date
- INSW 08-06-2025
- CNTA 08-12-2025
- Dividend Yield
- INSW 9.73%
- CNTA N/A
- EPS Growth
- INSW N/A
- CNTA N/A
- EPS
- INSW 6.47
- CNTA N/A
- Revenue
- INSW $860,606,000.00
- CNTA $15,000,000.00
- Revenue This Year
- INSW N/A
- CNTA N/A
- Revenue Next Year
- INSW $1.88
- CNTA N/A
- P/E Ratio
- INSW $6.36
- CNTA N/A
- Revenue Growth
- INSW N/A
- CNTA 118.88
- 52 Week Low
- INSW $27.20
- CNTA $9.10
- 52 Week High
- INSW $56.66
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- INSW 59.51
- CNTA 68.78
- Support Level
- INSW $40.35
- CNTA $15.05
- Resistance Level
- INSW $40.89
- CNTA $16.43
- Average True Range (ATR)
- INSW 1.00
- CNTA 0.74
- MACD
- INSW 0.17
- CNTA -0.00
- Stochastic Oscillator
- INSW 74.22
- CNTA 69.28
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.